Beam Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Beam Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $34.94M.
- Beam Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $107.18M, a 380.64% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $93.81M, a 73.93% increase year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $22.30M, a 85.87% decline year-over-year.
- Beam Therapeutics Inc. stock issued during period, value, new issues for fiscal 2020 was $188.32M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-09-30 | $34.94M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $107.18M 10-Q · filed 2023-11-08 | |
| 2023-03-31 | $93.81M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $22.30M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $53.94M 10-Q · filed 2023-11-08 | |
| 2021-09-30 | $318.61M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $157.78M 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $252.00M 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $188.32M 10-K · filed 2021-03-15 | |
| 2020-03-31 | $188.32M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |